Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TALL 104

Drug Profile

TALL 104

Alternative Names: ABIO-05/01; ABIO-0501; Human MHC non-restricted cytotoxic T-cell line - Galileo Research; TALL-104

Latest Information Update: 23 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wistar Institute
  • Developer Abiogen Pharma; Galileo Research; University of Texas M. D. Anderson Cancer Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer
  • No development reported Peritoneal cancer
  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 29 Jul 2015 No recent reports on development identified - Phase-I/II for Peritoneal cancer in Italy (IV & Intraperitoneal)
  • 13 Feb 2014 No development reported - Phase-II for Ovarian cancer in Italy (Parenteral)
  • 01 May 2013 Abiogen Pharma terminates phase I trial in Chronic myeloid leukaemia (combination therapy, second-line therapy or greater) in USA (NCT00415909)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top